Incyte Corp. and Merck have expanded their ongoing clinical collaboration to include a Phase III study evaluating the combination of epacadostat, Incyte’s investigational selective IDO1 inhibitor, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as first-line treatment for advanced or metastatic melanoma. The Phase III study, which is expected to begin in 1H16, will be co-funded by Incyte and Merck.   The companies have also agreed, for a period of two years, not to initiate new studi...